Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Demcizumab with Gemcitabine and Abraxane in Metastatic Pancreatic Cancer
NCT02289898Phase 2Completed
- Sponsor
- OncoMed Pharmaceuticals
- Start
- Apr 2015
- Primary completion
- May 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of demcizumab in pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by OncoMed Pharmaceuticals. Primary endpoint: Progression-Free Survival. Started Apr 2015; status: completed.
02
Drugs
demcizumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02289898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289898.